(Date:10/13/2008)...ontinuing Commitment by Financing All Cash Transa... Generation Enterprise ...ewswire-FirstCall/ -- Health,Systems Solutions, In...sdaq: EMAG ) today announced the signing of a def...tock of Emageon. The agreement was unanimously,app...
(Date:10/13/2008)... NSAID pain relievers, experts say , , ...killer Vioxx was pulled from the market in 2004 --... attack, stroke and death -- many assumed that sto... study finds that "the risk was increased close to... a year," said co-author Dr. Robert Bresalier, a p...
(Date:10/13/2008)...ng programs for inpatients that include follow-up ... improve patients, ability to stay smoke-free. An...t hospitals around the world finds that efforts fe...,s chances of success by 65 percent. The study l...arch and Treatment Center at Massachusetts General...
(Date:10/13/2008)...t the combination of low plasma levels of antioxid...iated with certain forms of the eye disease age-re...eport in the October issue of Archives of Ophthal..."The retina is vulnerable to the damaging effects ...tion in the article. "While wavelengths in the UV ...
Breaking Medicine News(10 mins):Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 2Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 3Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 4Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 5Health News:Health Systems Solutions Enters into Agreement to Acquire Emageon to Create Healthcare Technology Leader 6Health News:Vioxx's Heart Risk Lingered Long After Use Ended 2Health News:Vioxx's Heart Risk Lingered Long After Use Ended 3Health News:Intensive support programs can help hospitalized smokers stay smoke-free 2Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2(Date:10/13/2008)... advances study Study needed because of low ...13 /- Advanced Circulatory Systems, I...ed today that it has received,an additional $1.5 m...Health (NIH) to continue a study testing two devic...diac arrest outside a hospital. Whatcom County, WA...
(Date:10/13/2008)...face Treatment Maximizes,Endothelialization; Reduc...,Dual Antiplatelet Therapy, WASHINGTON, Oct. 13 /...Innovative Devices and Futuristic Therapies" sessi...ular Therapeutics (TCT) scientific,symposium, spon...resented,12-month follow-up data from the ATLANTA ...
(Date:10/13/2008)...r Populations Facilitates ...Newswire/ -- Rubicon Genomics, Inc. today,announce...samples for The,Cancer Atlas Genome Project., Rub...ize total genomic,DNA from 3,000 tissue and blood ...ex(TM) Whole Genome Amplification technology was j...
(Date:10/12/2008)...gned for more uniform drug ...Oct. 12 /- Boston,Scientifi...hensive data from,the TAXUS ATLAS clinical program...ingle-arm, historically controlled trials, which e... Stent System in a variety of,lesions and patient ...
Breaking Medicine Technology:Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6Autonomy 28TM 29 Lapro Angle 28TM 29 Articulating Laparoscopic Instruments Granted CE Mark 6910 1Autonomy 28TM 29 Lapro Angle 28TM 29 Articulating Laparoscopic Instruments Granted CE Mark 6910 2Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference 6907 1Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference 6907 2CryoLife Announces Management Promotions 6903 1CryoLife Announces Management Promotions 6903 2CryoLife Announces Management Promotions 6903 3Body Shaping Fuels Growth of 245 2 Billion Global Medical Aesthetic Market 6902 1Body Shaping Fuels Growth of 245 2 Billion Global Medical Aesthetic Market 6902 2...– Intercell AG (VSE,“ICLL”) has...; Co., Inc. on the results of a Phase I study invo...omparing safety and,immunogenicity of different do...taphylococcus aureus vaccine is based on a conserv... Antigen Identification,Program (AIP®) and was...
...ombination, PARSIPPANY, N.J., May 21, 2007 /PRNews...odipine besylate with the angiotensin,receptor blo...an,reductions in seated systolic and diastolic blo...ng to data presented at the,American Society of Hy...ng and Exposition (ASH 2007). The Phase III regist...
Other Medicine Technology:Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials 2Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials 3Amlodipine and Olmesartan Study Results Released; Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released; Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Ferris Smith Rongeurs, 12 overall length 300 mm.
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse.
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse.
It is designed for rigid skeletal fixation, and allows the surgeon greater freedom in positioning the fixation pins. The 3-point rigid skeletal fixation is designed for the supine, prone, lateral, or
Medicine Products: